deputy director for R&D&C
University Medical Center, Kazakhstan
Dear attendees and everyone,
The battle against COVID-19 is being conducted both in therapeutic-diagnostic as development of drugs and diagnostic tools, and preventive as development of vaccine preparations directions. However, no victorious paths are foreseen. COVID-19 and Influenza co-infection with non-communicable chronic diseases (NCDs) complicate the diagnosis, treatment, prognosis, and increase mortality rate. Pharmacologic and bio-vaccine treatment are not always can help to cure the acute respiratory diseases (ARD) due to they have wide side-effects, sensitivity and specificity, etc. during and post treatment period. Treatment of the ARDs is more difficult in patients with NCDs as type 2 diabetes (T2D), hypertension, and nonalcoholic steatohepatitis (NASH).
Some studies reported a high prevalence of overweight and obesity in patients experiencing a severe COVID course, with serious complications requiring hospitalization and admission to intensive care units. NCDs and the ARDs are spreading in countries with a higher rate of overweight. Acute and chronic inflammation in patients with overweight extreme difficulties in treatment and highlight the need for preventive measures.
Pharmacological treatment of ARDs with NASH is a great challenge for medicine, because the patients are often limited to take medicine due to persistent progression, increasing of hepatocellular injury/ inflammation, and medicinal overloading.
The purpose of our a 6-week open pilot prospective clinical trial was: to evaluate of our fast weight loss method on clinic and laboratory inflammation profile, metabolic profile, reactive oxygen species and body composition in patients with COVID and Influenza in comorbidity with T2D, hypertension, and NASH.
The study showed that the fast weight loss ‘ANADETO’ cured clinical, laboratory, and instrumental data of inflammation, improved glucose and lipids metabolism, normalized systolic/diastolic blood pressures and NASH’s biochemical outcomes, decreased reactive oxygen species, and allowed drugs reduction up to its complete withdrawal in patients with COVID and Influenza in comorbidity with T2D, hypertension, and NASH.
We as researchers have read the aim and scope of the American Society for Nutrition’s (ASN) flagship meeting “NUTRITION 2023”, and we are assuming that the results of the open pilot prospective clinical trial would concern your public readers for further discussion.
The study is original, and has not been previously published elsewhere.
Competing interests: Conflicts of interest were not declared by any author. All authors have contributed significantly, and that all authors are in agreement with the content of the manuscript.
Best respects,
Kuat Oshakbayev, MD, PhD, DMSc, professor
Aigul Durmanova, MD, PhD, DMSc
Zulfiya Zhankalova, MD, PhD, DMSc
Alisher Idrisov, MD, PhD, DMSc
Gulnara Bedelbayeva, MD, PhD, DMSc, associate professor
Meruyert Gazaliyeva, MD, PhD, professor
Altay Nabiyev, MD, PhD
Attila Tordai, PhD, DSc, professor
Bibazhar Dukenbayeva, MD, PhD, associate professor.